Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 5001

1.

An in vitro evaluation of drugs used in the Kenyan ART program.

Muriuki J, Ng'ang'a Z, Lihana R, Lwembe R, Mwangi J, Mwau M.

Pan Afr Med J. 2016 Mar 25;23:134. doi: 10.11604/pamj.2016.23.134.7157. eCollection 2016.

2.

HIV-1 Protease in the Fission Yeast Schizosaccharomyces pombe.

Benko Z, Elder RT, Li G, Liang D, Zhao RY.

PLoS One. 2016 Mar 16;11(3):e0151286. doi: 10.1371/journal.pone.0151286. eCollection 2016.

3.

Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival.

Chen M, Wong WW, Law MG, Kiertiburanakul S, Yunihastuti E, Merati TP, Lim PL, Chaiwarith R, Phanuphak P, Lee MP, Kumarasamy N, Saphonn V, Ditangco R, Sim BL, Nguyen KV, Pujari S, Kamarulzaman A, Zhang F, Pham TT, Choi JY, Oka S, Kantipong P, Mustafa M, Ratanasuwan W, Durier N, Chen YM.

PLoS One. 2016 Mar 2;11(3):e0150512. doi: 10.1371/journal.pone.0150512. eCollection 2016.

4.

The Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve Slope.

Chang S, Zhuang D, Guo W, Li L, Zhang W, Liu S, Li H, Liu Y, Bao Z, Han J, Song H, Li J.

PLoS One. 2016 Mar 1;11(3):e0149467. doi: 10.1371/journal.pone.0149467. eCollection 2016.

5.

Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals.

Trejbalová K, Kovářová D, Blažková J, Machala L, Jilich D, Weber J, Kučerová D, Vencálek O, Hirsch I, Hejnar J.

Clin Epigenetics. 2016 Feb 19;8:19. doi: 10.1186/s13148-016-0185-6. eCollection 2016.

6.

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.

López-Cortés LF, Castaño MA, López-Ruz MA, Rios-Villegas MJ, Hernández-Quero J, Merino D, Jiménez-Aguilar P, Marquez-Solero M, Terrón-Pernía A, Tellez-Pérez F, Viciana P, Orihuela-Cañadas F, Palacios-Baena Z, Vinuesa-Garcia D, Fajardo-Pico JM, Romero-Palacios A, Ojeda-Burgos G, Pasquau-Liaño J.

PLoS One. 2016 Feb 12;11(2):e0148924. doi: 10.1371/journal.pone.0148924. eCollection 2016.

7.

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.

Dinges W, Girard PM, Podzamczer D, Brockmeyer NH, García F, Harrer T, Lelievre JD, Frank I, Colin De Verdière N, Yeni GP, Ortega Gonzalez E, Rubio R, Clotet Sala B, DeJesus E, Pérez-Elias MJ, Launay O, Pialoux G, Slim J, Weiss L, Bouchaud O, Felizarta F, Meurer A, Raffi F, Esser S, Katlama C, Koletar SL, Mounzer K, Swindells S, Baxter JD, Schneider S, Chas J, Molina JM, Koutsoukos M, Collard A, Bourguignon P, Roman F.

Medicine (Baltimore). 2016 Feb;95(6):e2673. doi: 10.1097/MD.0000000000002673.

8.

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment.

Vandewalle B, Llibre JM, Parienti JJ, Ustianowski A, Camacho R, Smith C, Miners A, Ferreira D, Félix J.

PLoS One. 2016 Feb 12;11(2):e0149007. doi: 10.1371/journal.pone.0149007. eCollection 2016.

9.

Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.

Stoszko M, De Crignis E, Rokx C, Khalid MM, Lungu C, Palstra RJ, Kan TW, Boucher C, Verbon A, Dykhuizen EC, Mahmoudi T.

EBioMedicine. 2015 Nov 27;3:108-21. doi: 10.1016/j.ebiom.2015.11.047. eCollection 2016 Jan.

10.

Non-Classical Monocytes and Monocyte Chemoattractant Protein-1 (MCP-1) Correlate with Coronary Artery Calcium Progression in Chronically HIV-1 Infected Adults on Stable Antiretroviral Therapy.

Zungsontiporn N, Tello RR, Zhang G, Mitchell BI, Budoff M, Kallianpur KJ, Nakamoto BK, Keating SM, Norris PJ, Ndhlovu LC, Souza SA, Shikuma CM, Chow DC.

PLoS One. 2016 Feb 11;11(2):e0149143. doi: 10.1371/journal.pone.0149143. eCollection 2016.

11.

Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.

Mirembe BG, Kelly CW, Mgodi N, Greenspan S, Dai JY, Mayo A, Piper J, Akello CA, Kiweewa FM, Magure T, Nakabiito C, Marrazzo JM, Chirenje ZM, Riddler SA; MTN-003B Protocol Team.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):287-94. doi: 10.1097/QAI.0000000000000858.

12.

Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo.

Simonetti FR, Sobolewski MD, Fyne E, Shao W, Spindler J, Hattori J, Anderson EM, Watters SA, Hill S, Wu X, Wells D, Su L, Luke BT, Halvas EK, Besson G, Penrose KJ, Yang Z, Kwan RW, Van Waes C, Uldrick T, Citrin DE, Kovacs J, Polis MA, Rehm CA, Gorelick R, Piatak M, Keele BF, Kearney MF, Coffin JM, Hughes SH, Mellors JW, Maldarelli F.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1883-8. doi: 10.1073/pnas.1522675113. Epub 2016 Feb 8.

13.

ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.

Olesen R, Swanson MD, Kovarova M, Nochi T, Chateau M, Honeycutt JB, Long JM, Denton PW, Hudgens MG, Richardson A, Tolstrup M, Østergaard L, Wahl A, Garcia JV.

J Clin Invest. 2016 Mar 1;126(3):892-904. doi: 10.1172/JCI64212. Epub 2016 Feb 8.

14.

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients.

Gonzalez-Serna A, Genebat M, Ruiz-Mateos E, Leal M.

Drug Des Devel Ther. 2016 Jan 18;10:353-4. doi: 10.2147/DDDT.S100639. eCollection 2016. No abstract available.

15.

Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects.

Li Y, Xie J, Han Y, Wang H, Lv W, Guo F, Qiu Z, Li Y, Du S, Song X, Zhu T, Thio CL, Li T.

Medicine (Baltimore). 2016 Feb;95(5):e2660. doi: 10.1097/MD.0000000000002660.

16.

Clinical Evaluation of an Affordable Qualitative Viral Failure Assay for HIV Using Dried Blood Spots in Uganda.

Balinda SN, Ondoa P, Obuku EA, Kliphuis A, Egau I, Bronze M, Kasambula L, Schuurman R, Spieker N, Rinke de Wit TF, Kityo C; ART–A consortium.

PLoS One. 2016 Jan 29;11(1):e0145110. doi: 10.1371/journal.pone.0145110. eCollection 2016.

17.

Persistent HIV-1 replication maintains the tissue reservoir during therapy.

Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Kosakovsky Pond SL, Chung YS, Penugonda S, Chipman JG, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, Wolinsky SM.

Nature. 2016 Feb 4;530(7588):51-6. doi: 10.1038/nature16933. Epub 2016 Jan 27.

18.

Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.

Sweet DE, Altice FL, Cohen CJ, Vandewalle B.

PLoS One. 2016 Jan 25;11(1):e0147821. doi: 10.1371/journal.pone.0147821. eCollection 2016.

19.

Mutations Related to Antiretroviral Resistance Identified by Ultra-Deep Sequencing in HIV-1 Infected Children under Structured Interruptions of HAART.

Vazquez-Guillen JM, Palacios-Saucedo GC, Rivera-Morales LG, Garcia-Campos J, Ortiz-Lopez R, Noguera-Julian M, Paredes R, Vielma-Ramirez HJ, Ramirez TJ, Chavez-Garcia M, Lopez-Guillen P, Briones-Lara E, Sanchez-Sanchez LM, Vazquez-Martinez CA, Rodriguez-Padilla C.

PLoS One. 2016 Jan 25;11(1):e0147591. doi: 10.1371/journal.pone.0147591. eCollection 2016.

20.

Unfolding the HIV-1 reverse transcriptase RNase H domain--how to lose a molecular tug-of-war.

Zheng X, Pedersen LC, Gabel SA, Mueller GA, DeRose EF, London RE.

Nucleic Acids Res. 2016 Feb 29;44(4):1776-88. doi: 10.1093/nar/gkv1538. Epub 2016 Jan 14.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk